Control Resonant brings a new paranatural crisis to PS5, out 2026

Remedy Entertainment unveiled Control Resonant, the sequel to 2019’s Control, at The Game Awards; the game shifts focus to Dylan Faden and is set in a paranaturally warped Manhattan. Billed as an open-ended third-person action‑RPG with deep progression, a shapeshifting melee weapon and replayable zones, Remedy says it is their biggest game and intends to release it for PlayStation 5 in 2026. For investors, Resonant represents a significant IP expansion and multi‑year product pipeline that could drive revenue and engagement for Remedy, with outcomes dependent on execution and market reception upon its 2026 launch.

Analysis

Remedy Entertainment announced Control Resonant, a sequel to 2019’s Control, at The Game Awards with a reveal trailer and confirmed a PlayStation 5 release in 2026; the studio describes it as the biggest title it has developed and shifts narrative focus to Dylan Faden after years in confinement. The title is billed as a third-person, open-ended action-RPG set in a paranaturally warped Manhattan with expansive zones, branching missions, replayability, a deep progression system and a signature shapeshifting melee weapon called the Aberrant.

Design choices — open zones, multiple combat styles, upgradeable weapons and replayable content — position Resonant as an IP-expansion title aimed at increasing engagement and broadening the franchise’s audience, while Remedy explicitly frames the game as accessible to newcomers and appealing to returning players. The company references strong PlayStation audience support from the first game, suggesting platform affinity is a strategic factor in initial positioning.

From an investment perspective the announcement is mildly positive in sentiment (score ~0.3) but low in immediate market impact (~0.28), reflecting upside tied to long lead-time execution and reception risks. Key near-term risks are development execution through 2026, marketing and platform distribution details, and the potential for timing to delay revenue realization despite meaningful franchise expansion potential.

Key Decisions for Investors

• Monitor development milestones, extended gameplay reveals and early reviews through 2024–2026 before increasing exposure, as the title’s commercial outcome hinges on execution and reception
• Consider modest long-term exposure to Remedy-linked IP growth given the studio’s stated ambition and PlayStation audience affinity, but size positions conservatively because revenue is backloaded to a 2026 release
• Watch platform and distribution announcements closely—any extended PlayStation exclusivity or broader multi-platform plans will materially affect addressable market and revenue forecasts
• Use event-driven hedges or option strategies to express a conditional upside view while limiting downside from development delays or underwhelming launch reception